Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Major Shareholder Barry Canton Sells 143,808 Shares

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) major shareholder Barry Canton sold 143,808 shares of the stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $1.75, for a total transaction of $251,664.00. Following the sale, the insider now directly owns 15,846,844 shares of the company’s stock, valued at approximately $27,731,977. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Barry Canton also recently made the following trade(s):

  • On Thursday, January 19th, Barry Canton sold 199,843 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.71, for a total transaction of $341,731.53.
  • On Tuesday, January 17th, Barry Canton sold 151,530 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.86, for a total transaction of $281,845.80.
  • On Thursday, January 12th, Barry Canton sold 190,343 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.70, for a total transaction of $323,583.10.
  • On Tuesday, January 10th, Barry Canton sold 157,798 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.50, for a total transaction of $236,697.00.
  • On Wednesday, January 4th, Barry Canton sold 37,650 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.56, for a total transaction of $58,734.00.
  • On Monday, December 19th, Barry Canton sold 206,448 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.67, for a total transaction of $344,768.16.
  • On Thursday, December 15th, Barry Canton sold 103,547 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.61, for a total transaction of $166,710.67.
  • On Tuesday, December 13th, Barry Canton sold 98,934 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.89, for a total transaction of $186,985.26.
  • On Thursday, December 8th, Barry Canton sold 97,204 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.79, for a total transaction of $173,995.16.
  • On Tuesday, December 6th, Barry Canton sold 103,392 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.73, for a total transaction of $178,868.16.

Ginkgo Bioworks Stock Down 1.6 %

NYSE:DNA opened at $1.81 on Wednesday. The firm has a 50-day simple moving average of $1.80 and a two-hundred day simple moving average of $2.51. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $6.38. The firm has a market cap of $3.51 billion, a P/E ratio of -0.79 and a beta of 0.68. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.67 and a current ratio of 11.71.

Ginkgo Bioworks (NYSE:DNAGet Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). Ginkgo Bioworks had a negative return on equity of 85.90% and a negative net margin of 668.49%. The company had revenue of $66.40 million during the quarter, compared to the consensus estimate of $54.28 million. Analysts predict that Ginkgo Bioworks Holdings, Inc. will post -1.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

DNA has been the subject of a number of recent research reports. Morgan Stanley initiated coverage on shares of Ginkgo Bioworks in a research report on Tuesday, October 4th. They set an “equal weight” rating and a $5.00 price target for the company. Raymond James lowered their price target on shares of Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating for the company in a research report on Tuesday, November 22nd. Berenberg Bank initiated coverage on shares of Ginkgo Bioworks in a research report on Monday, November 28th. They set a “buy” rating and a $6.00 price target for the company. Finally, BTIG Research lowered their price target on shares of Ginkgo Bioworks to $4.00 in a research report on Thursday, November 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Ginkgo Bioworks currently has an average rating of “Hold” and an average price target of $5.92.

Institutional Trading of Ginkgo Bioworks

A number of large investors have recently made changes to their positions in the stock. Almanack Investment Partners LLC. grew its stake in shares of Ginkgo Bioworks by 22.3% in the second quarter. Almanack Investment Partners LLC. now owns 17,850 shares of the company’s stock worth $42,000 after acquiring an additional 3,250 shares during the period. Treasurer of the State of North Carolina boosted its holdings in shares of Ginkgo Bioworks by 1.3% in the third quarter. Treasurer of the State of North Carolina now owns 351,677 shares of the company’s stock worth $1,097,000 after buying an additional 4,540 shares during the last quarter. Formidable Asset Management LLC boosted its holdings in shares of Ginkgo Bioworks by 32.1% in the second quarter. Formidable Asset Management LLC now owns 20,332 shares of the company’s stock worth $64,000 after buying an additional 4,946 shares during the last quarter. Bradley Foster & Sargent Inc. CT boosted its holdings in shares of Ginkgo Bioworks by 7.3% in the second quarter. Bradley Foster & Sargent Inc. CT now owns 74,390 shares of the company’s stock worth $177,000 after buying an additional 5,035 shares during the last quarter. Finally, IHT Wealth Management LLC boosted its holdings in shares of Ginkgo Bioworks by 11.4% in the third quarter. IHT Wealth Management LLC now owns 51,745 shares of the company’s stock worth $161,000 after buying an additional 5,275 shares during the last quarter. 61.83% of the stock is currently owned by institutional investors.

About Ginkgo Bioworks

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Recommended Stories

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.